Skip to search formSkip to main contentSkip to account menu

ONYX015

Known as: CI-1042, ONYX-015, CI1042 
An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antineoplastic AgentsViral Vaccines
Positive Regulation of Cytolytic Process

Narrower (1)

dl1520

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Lung Cancer Patients Cancer Cell Lines and Primary Cultures Freshly Made from ONYX-015 Works Synergistically with Chemotherapy in Lung
ABSTRACT p53 mutations and loss of heterozygosity (LOH) have been detected in > 50% of lung cancers. Wild-type p53 can prevent… 
2005
2005
Clinical trials: The sensitizing side of Onyx-015
New clinical trial data on the use of the ONYX-015 adenovirus as a chemosensitizing agent indicate that further study of this… 
2005
2005
p53: son rôle dans les mécanismes de résistance. Sait-on s’en servir en pratique cancérologique en 2005?
Résumé:p53 est une protéine impliquée dans la réparation de l’ADN ou l’induction de l’apoptose après un stress cellulaire. C’est… 
2005
2005
Research Highlights
The modified adenovirus ONYX-015 lacks the E1B-55K gene product and shows promise in clinical trials as a treatment for cancer… 
2005
2005
The Influence of Coxsackievirus-adenovirus Receptor and p53 Status on the Antitumor Activity of ONYX-015
Objective:To study the selective replication and cytotoxicity of a tumor-specific replicating adenovirus ONYX-015 in tumor cells… 
2003
2003
Replication of an E 1 B 55-Kilodalton Protein-Deficient Adenovirus ( ONYX-015 ) Is Restored by Gain-of-Function Rather than Loss-of-Function p 53 Mutants
ONYX-015 (dl1520) is an E1B 55-kilodalton protein-deficient replicating adenovirus that is currently in clinical trials as an… 
Review
2002
Review
2002
New cancer agent ONYX-015: selectively replicated adenovirus dl1520
Selectively replicating adenovirus dl1520 is a new gene virus therapeutic agent to cancer in the phase Ⅲ clinical trial now. This… 
2001
2001
Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication?
2001
2001
Advances in Brief p 14 ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p 53
ONYX-015 has been reported to kill selectively tumor cells lacking functional p53. Genetic alterations of INK4a/ARF locus, which… 
2000
2000
A clinical study of a single pre-operative injection of Onyx-015 attenuated adenovirus in squamous carcinoma of the head and neck.